PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:MD - US58502B1061 - Common Stock
24.09 USD
-0.36 (-1.47%)
24.09 USD
0 (0%)
Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 101 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of MD get a neutral evaluation. Nothing too spectacular is happening here. MD scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes MD very considerable for value investing!
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
In the past year MD had a positive cash flow from operations.
In multiple years MD reported negative net income over the last 5 years.
In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
MD has a better Return On Assets (7.37%) than 90.10% of its industry peers.
With an excellent Return On Equity value of 18.21%, MD belongs to the best of the industry, outperforming 85.15% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 10.25%, MD belongs to the top of the industry, outperforming 81.19% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 9.26%.
The last Return On Invested Capital (10.25%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD's Profit Margin of 8.44% is amongst the best of the industry. MD outperforms 89.11% of its industry peers.
MD's Operating Margin of 12.20% is amongst the best of the industry. MD outperforms 81.19% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
MD has more shares outstanding than it did 1 year ago.
MD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MD has a worse debt to assets ratio.
2.2 Solvency
MD has an Altman-Z score of 2.29. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of MD (2.29) is comparable to the rest of the industry.
The Debt to FCF ratio of MD is 2.20, which is a good value as it means it would take MD, 2.20 years of fcf income to pay off all of its debts.
MD has a better Debt to FCF ratio (2.20) than 80.20% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that MD is somewhat dependend on debt financing.
MD's Debt to Equity ratio of 0.65 is in line compared to the rest of the industry. MD outperforms 56.44% of its industry peers.
Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.29 |
ROIC/WACC1.16
WACC8.83%
2.3 Liquidity
A Current Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
MD's Current ratio of 1.83 is fine compared to the rest of the industry. MD outperforms 71.29% of its industry peers.
A Quick Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
MD has a better Quick ratio (1.83) than 74.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
Measured over the past years, MD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.01% on average per year.
The Revenue has decreased by -4.21% in the past year.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
The Earnings Per Share is expected to grow by 7.64% on average over the next years.
Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 2.71% on average per year.
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y7.64%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.71%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.81, the valuation of MD can be described as reasonable.
Based on the Price/Earnings ratio, MD is valued cheaply inside the industry as 87.13% of the companies are valued more expensively.
MD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.31.
The Price/Forward Earnings ratio is 12.77, which indicates a correct valuation of MD.
Based on the Price/Forward Earnings ratio, MD is valued cheaper than 84.16% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.81 | ||
| Fwd PE | 12.77 |
4.2 Price Multiples
80.20% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
90.10% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.57 | ||
| EV/EBITDA | 8.22 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y12.52%
EPS Next 3Y9.51%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.09
-0.36 (-1.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change-2.05%
Ins Owners1.9%
Ins Owner Change6.32%
Market Cap2.07B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (-4.03%)
Short Float %3.54%
Short Ratio3.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)36.68%
PT rev (3m)32.22%
EPS NQ rev (1m)16.45%
EPS NQ rev (3m)18.43%
EPS NY rev (1m)0%
EPS NY rev (3m)7.69%
Revenue NQ rev (1m)0.9%
Revenue NQ rev (3m)1.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.81 | ||
| Fwd PE | 12.77 | ||
| P/S | 1.08 | ||
| P/FCF | 7.57 | ||
| P/OCF | 7.13 | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.22 |
EPS(TTM)2.04
EY8.47%
EPS(NY)1.89
Fwd EY7.83%
FCF(TTM)3.18
FCFY13.21%
OCF(TTM)3.38
OCFY14.02%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.49
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.29 |
F-Score8
WACC8.83%
ROIC/WACC1.16
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
How financially healthy is PEDIATRIX MEDICAL GROUP INC?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 5 / 10.
What is the expected EPS growth for PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Earnings per Share (EPS) of PEDIATRIX MEDICAL GROUP INC (MD) is expected to grow by 23.94% in the next year.